NeuroPace (NPCE) CMO has 358 shares withheld for RSU tax
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
NeuroPace Inc's chief medical officer reports a small share disposition tied to tax withholding. On February 27, 2026, 358 shares of common stock were withheld at $14.58 per share to satisfy tax obligations from a restricted stock unit vesting, rather than an open-market sale. Following this tax-withholding disposition, Martha Morrell directly held 74,964 shares of NeuroPace common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Morrell Martha
Role
CHIEF MEDICAL OFFICER
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Tax Withholding | Common Stock | 358 | $14.58 | $5K |
Holdings After Transaction:
Common Stock — 74,964 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What insider transaction did NeuroPace (NPCE) report for Martha Morrell?
NeuroPace reported a small tax-related share disposition by chief medical officer Martha Morrell. On February 27, 2026, 358 common shares were withheld to cover tax obligations from a restricted stock unit vesting, rather than sold in the open market.
Was the NeuroPace (NPCE) Form 4 a market sale by the chief medical officer?
No, the Form 4 reflects tax withholding, not a market sale. Shares were withheld by NeuroPace to cover tax obligations from a restricted stock unit vesting, so it does not represent an open-market sell order executed by Martha Morrell.
What does transaction code F mean in the NeuroPace (NPCE) Form 4?
Transaction code F indicates shares were used to pay exercise price or taxes. In this case, NeuroPace withheld 358 common shares to satisfy tax withholding obligations from a restricted stock unit vesting for chief medical officer Martha Morrell.